Part 3/10:
According to Brian McName, chairman of CSL, there is an opportunity for the Australian government to negotiate more effectively with the US administration. He suggests that Australia could make small concessions—such as streamlining the approval process for American innovative drugs via the PBS—without compromising the scheme’s integrity. These minor adjustments could persuade the US to ease or lift the tariffs, especially if combined with negotiations around pricing mechanisms that favor faster drug approvals.